NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Sat, 27 Sept · 15:46 IST

Results of the Postal Ballot Notice regarding appointment of Dr. Ravi Shankar Gopinath as an Independent Director of the Company, along the Scrutinizer s Report

Management Changes View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Neuland Laboratories has received shareholder approval for the appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847) as an Independent Director for a 5-year term effective August 1, 2025. The special resolution was passed through a postal ballot (e-voting) with an overwhelming 99.99% of votes in favor — 79,96,901 votes for versus just 239 against. Promoters voted 100% in favor, public institutions voted 100% in favor, and public non-institutions voted 99.83% in favor. Total of 45,705 shareholders were on record, and 472 members cast their votes. The scrutinizer's report was issued by D. Hanumanta Raju & Co., Company Secretaries.

Likely market impact

This is a routine governance update with no material impact on shareholders or stock price. The near-unanimous approval (over 99.99%) reflects strong shareholder support and indicates a smooth, uncontested board appointment.